Stock Under $10 with 50-100% upside potential - 14 Days FREE!

BC-Business News Digest

Business News at 5:30 p.m.

The supervisor is Richard Jacobsen (800-845-8450, ext. 1680). For photos, ext. 1900. For graphics and interactives, ext. 7636. Expanded AP content can be obtained from http://www.apexchange.com. For access to AP Exchange and other technical issues, contact customersupport(at)ap.org or call 877-836-9477.

If you have questions about transmission of financial market listings, please call 800-3AP-STOX.

A selection of top photos can be found at http://bit.ly/APTopPhotos

NEW THIS DIGEST:

⿿ Adds: BRITAIN-ECONOMY, APPLE-INVESTORS

⿿ Updates: WALL STREET

TOP STORIES:

BOEING 787-BATTERY FIX

WASHINGTON ⿿ Boeing took a major step toward getting its 787 "Dreamliners" flying again, proposing a fix for the plane's troubled batteries that could allow flights to resume as early as April, congressional officials say. The next question is whether the Federal Aviation Administration will agree to a plan that appears focused on containing a fire and let the planes fly even though the root cause of the battery problems isn't yet known. By Joan Lowy and Joshua Freed.

AP photo.

With:

⿿ JAPAN-BOEING 787 ⿿ Japanese authorities have identified the causes of fuel leaks and other problems with Boeing's 787 but are still investigating the more serious battery problem that forced an emergency landing in January and the worldwide grounding of the jets.

WIRELESS SHOW

NEW YORK ⿿When the top executives of the world's wireless industry gather next week in Barcelona for their annual trade show, cellphones will be taking a back seat to discussion of cars, electric meters and insulin monitors. Now that most people have cellphones, the industry is looking to connect other devices to keep growth going. Organizers expect record attendance for the show and a boost to Barcelona's struggling economy. By Technology Writer Peter Svensson.

BREAST CANCER DRUG-ROCHE

WASHINGTON ⿿ The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. Cancer researchers say the drug may offer a clear advantage over older drugs because it delivers more medication with fewer side effects. By Business Writer Matthew Perrone.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs